Abstract Body

Background: Pathobiology of HIV-associated lymphoma may be changing in the era of effective antiretroviral therapy (ART). Lymphoma incidence is increased soon after ART, perhaps due to the immune reconstitution inflammatory syndrome (IRIS). Methodology: In the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS), we characterized patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1996 and 2011 as: (1) on ART ≤6 months with ≥0.5 log10copies/mL reduction in HIV RNA (unmasking lymphoma IRIS); (2) on ART without IRIS; or (3) off ART. CD4 and HIV RNA during the 12 months before and after lymphoma diagnosis, stratified by IRIS and ART status, were assessed using individual patient-level CD4 and HIV RNA curves. Summative curves were derived by plotting median and interquartile values at each monthly time point across all patients within each group. Results: Of 24,203 HIV-infected individuals enrolled in CNICS, 482 (2%) were diagnosed with lymphoma between 1996 and 2011. Of these, 56 (12%) had unmasking lymphoma IRIS, 175 (36%) were on ART without IRIS, and 251 (52%) were off ART. Unmasking lymphoma IRIS cases were on ART for 2.2 months (IQR 0.9-3.5), and 48% had HIV RNA <400 copies/mL. On ART cases without IRIS were on ART for 20.3 months (IQR 7.5-42.9), and 58% had HIV RNA <400 copies/mL. Median CD4 and HIV RNA during the 12 months before and after lymphoma diagnosis are shown in Figure 1. During the 24-month window, there were 3439 CD4 measures for the entire study population [median 8 (IQR 5-10) per patient], and 3266 HIV RNA measures [median 7 (IQR 5-10) per patient]. IRIS cases demonstrated marked reductions in HIV RNA after ART in the months before lymphoma diagnosis, without significant CD4 increases. In the 12 months after lymphoma diagnosis, IRIS cases demonstrated modest CD4 increases. On ART cases without IRIS demonstrated modest CD4 increases and reductions in HIV RNA after lymphoma diagnosis. Off ART cases demonstrated robust CD4 increases and reductions in HIV RNA after lymphoma diagnosis, resulting from ART initiation within six months in 198 of 251 (79%) patients. Conclusions: In the ART era, HIV-associated lymphoma develops in different immunologic and virologic contexts. The extent to which these differences influence histology, biology, and clinical outcomes remains unclear. Attenuated CD4 increases soon after ART initiation, despite HIV RNA suppression, might suggest developing lymphoma.